건강한 자원자에서 테오브로민 현탁액과 캡슐의 약동학 특성에 관한 비교 연구

Comparative Evaluation of Pharmacokinetic Properties between Theobromine Suspension and Capsule Formulations in Healthy Volunteers

  • 김재우 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김정렬 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 임경수 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 김보형 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 심준화 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 윤서현 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 이경훈 (성균관대학교 의과대학 분자세포생물학교실) ;
  • 유경상 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 신상구 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과) ;
  • 장인진 (서울대학교 의과대학 약리학교실 및 서울대학교병원 임상약리학과)
  • Kim, Jae-Woo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Kim, Jung-Ryul (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Lim, Kyoung-Soo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Kim, Bo-Hyung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shim, Jun-Hwa (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Yoon, Seo-Hyun (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Lee, Kyung-Hoon (Department of Molecuar Cell Biology, Sungkyunkwan University School of Medicine) ;
  • Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) ;
  • Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital)
  • 투고 : 2009.12.15
  • 심사 : 2009.12.19
  • 발행 : 2009.12.30

초록

Background: Theobromine, an alkaloid naturally present in green tea, coffee, and cocoa, is known to possess properties of cardiac stimulation and antitussive effects. The aim of this study was to compare the pharmacokinetic (PK) characteristics of two different formulations (suspension and capsule) of theobromine in healthy male volunteers. Methods: A randomized, open-label, multiple-dosing, two-treatment, two-period, two-sequence, crossover study was conducted in Clinical Trials Center, Seoul National University Hospital with 12 healthy male volunteers. Subjects orally received either theobromine suspension 300 mg or capsule 300 mg twice daily for 4 days and crossover phases were separated by a 7-day washout period. Plasma samples were collected before dosing and up to 12 hr after the last administration. Plasma theobromine concentrations were determined by liquid chromatography-tandem mass spectrometry. PK parameters were estimated by a non-compartmental analysis. Results: Median time to peak concentration of theobromine suspension and capsule groups ere 0.33 and 2.50 hr, respectively. The mean [SD] values for peak concentaration at steady state ($C_{max,ss}$) and area under the plasma concentration-time curve during dosing interval at steady state ($AUC_{\tau,ss}$) for suspension (13.90 [3.66] mg/L and 113.31 [31.95] $hr^*mg/L$) did not differ statistically from those of capsule (13.26[3.76] mg/L and 122.96[41.47] $hr^*mg/L$). The geometric mean ratios (90% confidence intervals) for suspension to capsule were 1.05 (0.95-1.16) for $C_{max,ss}$ and 0.92 (0.85-1.00) for $AUC_{\tau,ss}$. Conclusion: These findings suggest that theobromine suspension 300 mg is similar to the corresponding dose of capsule 300 mg in terms of pharmacokinetic properties except the time to peak concentration at steady state.

키워드

참고문헌

  1. Rodopoulos, N., L. Hojvall, and A. Norman, Elimination of theobromine metabolites in healthy adults. Scand J Clin Lab Invest, 1996. 56(4): p. 373-83. https://doi.org/10.3109/00365519609090590
  2. Lelo, A., et al., Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol, 1986. 22(2): p. 183-6. https://doi.org/10.1111/j.1365-2125.1986.tb05247.x
  3. Goodman, L.S., et al., Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. 2006, New York: McGraw-Hill. xxiii, 2021 p.
  4. Sweetman, S.C., Martindale : the complete drug reference. 35th ed. 2007, London: Pharmaceutical Press. 2 v. (xiii, 3322 p.).
  5. Simons, F.E., et al., The bronchodilator effect and pharmacokinetics of theobromine in young patients with asthma. J Allergy Clin Immunol, 1985. 76(5): p. 703-7. https://doi.org/10.1016/0091-6749(85)90674-8
  6. Usmani, O.S., et al., Theobromine inhibits sensory nerve activation and cough. FASEB J, 2005. 19(2): p. 231-3.
  7. Gates, S. and J.O. Miners, Cytochrome P450 isoform selectivity in human hepatic theobromine metabolism. Br J Clin Pharmacol, 1999. 47(3): p. 299-305. https://doi.org/10.1046/j.1365-2125.1999.00890.x
  8. Hsuan, F.C., Estimating treatment means in a mixed-effect ANOVA model for bioequivalence studies. Biometrics, 1993. 49(3):p. 703-13. https://doi.org/10.2307/2532191
  9. FDA, Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. March 2003.
  10. Hunt, T., R. Geetha, and E. Warga, The bioavailability of desogestrel/ethinyl estradiol tablets relative to the oral solution. Clin Drug Investig, 1998. 15(6): p. 507-14. https://doi.org/10.2165/00044011-199815060-00007
  11. Pescovitz, M.D., et al., Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc, 2007. 39(10): p. 3111-6.
  12. Gibaldi, M. and D. Perrier, Pharmacokinetics. 2nd ed. Drugs and the pharmaceutical sciences ;. 1982, New York: M. Dekker. viii, 494 p.
  13. van den Tweel, E.R., M. Relleke, and P. Muniz Piniella, Paroxetine oral solution is bioequivalent to paroxetine tablets-advantages of the solution. Int J Clin Pharmacol Ther, 2007. 45(11): p. 611-6. https://doi.org/10.5414/CPP45611
  14. van Os, S., M. Relleke, and P.M. Piniella, Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets. Int J Clin Pharmacol Ther, 2007. 45(5): p. 293-9. https://doi.org/10.5414/CPP45293
  15. Bauer, L.A., Applied clinical pharmacokinetics. 2nd ed. 2008, New York: McGraw-Hill Medical. xiv, 826 p.
  16. Coupez, R., et al., Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. J Clin Pharmacol, 2003. 43(12): p. 1370-6. https://doi.org/10.1177/0091270003258173
  17. Apter, A.J., et al., Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med, 1998. 157(6 Pt 1): p.1810-7. https://doi.org/10.1164/ajrccm.157.6.9712007